EUVIMEDOpdag EUVIMED
Open access

Lung-Targeted Delivery of Nebulized α-Asaronol Attenuates Airway Inflammation and Hyperresponsiveness in Murine Asthma Models

Yajun Bai iD, Xiaolong Zhao, Fei Wang, Dan Liu, Yujie Diao, Ying Sun, Yingying Zhao, Liyuan Zhang, Yujun Bai, Shixiang Wang, Pu Jia iD, Ye Zhao and 1 more

ACS Pharmacology & Translational Science · 2026-08-14 · 9 (8) · 2343-2357

DOI: 10.1021/acsptsci.6c00367 ↗

At a glance

Journal article in ACS Pharmacology & Translational Science, published online on 2026-07-23. Written by Yajun Bai and 12 co-authors. Institution: Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, The College of Life Sciences, Northwest University, Xi'…. 52 references. The full text is freely available in PubMed Central. Funded by: Key Research and Development Projects of Shaanxi Province, Shaanxi Province Qinchuangyuan 'Scientists + Engineers' Team Building Initiative, Critical Core Technology Breakthrough Project in Key Industrial Chains of Shaanxi Province.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Acorus tatarinowii, a traditional Chinese medicinal herb, is used clinically to treat neurological and respiratory disorders. Our previous work showed that α-asaronol (α-AOL), a low-toxicity natural constituent of A. tatarinowii, exerts robust antiepileptic effects through γ-aminobutyric acid (GABA)ergic modulation. Given the critical role of the peripheral GABAergic system in asthma pathogenesis and inflammation regulation, the therapeutic potential of α-AOL for asthma warrants investigation. This study evaluated the efficacy, safety, and pulmonary targeting of both nebulized and oral α-AOL. Murine asthma models were established using ovalbumin (OVA) and house dust mite (HDM). Both nebulized α-AOL (5, 10, 20 mg/kg) and oral α-AOL were administered, with α-asarone, and albuterol as references. Histological, biochemical, and functional assessments were performed to evaluate lung inflammation, mucus secretion, cytokine levels (IL-4, IL-5, IL-13, TNF-α), airway smooth muscle (ASM) relaxation, and airway hyperresponsiveness (AHR). Pharmacokinetic and safety profiles were determined via HPLC tissue distribution analysis, human ether-à-go-go related gene (hERG) assays, and monitoring of respiratory and cardiovascular function. Nebulized α-AOL dose-dependently alleviated OVA/HDM-induced airway inflammation, characterized by reduced inflammatory cell infiltration, cytokine release, mucus hypersecretion, and AHR. It also induced concentration-dependent ASM relaxation and demonstrated dual therapeutic activity by both preventing and reversing methacholine (Mch)-induced acute bronchospasm. Nebulization provided sustained lung targeting (≥60 min retention). α-AOL exhibited negligible hERG inhibition (IC50 > 100 μM), no adverse respiratory effects, and no significant impact on blood pressure. In conclusion, nebulized and oral α-AOL possesses potent anti-inflammatory and bronchodilatory activities; the nebulized formulation shows favorable lung-targeted delivery and an excellent safety profile, positioning it as a promising inhaled candidate for asthma therapy, particularly in pediatric populations.

Subjects

Author keywords

airway hyperresponsivenessanti-inflammationasthmabronchodilationnebulized administrationα-asaronol

Authors and institutions

  • Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, The College of Life Sciences, Northwest University, Xi'an 710069, P. R. China.
  • Hong-taoism Research Institute of Analytical Science and Technology Ltd., Shaanxi Province, Xi'an 710068, P. R. China.

ORCID profiles: Yajun Bai, Pu Jia

Funding

  • Key Research and Development Projects of Shaanxi Province
  • Shaanxi Province Qinchuangyuan 'Scientists + Engineers' Team Building Initiative
  • Critical Core Technology Breakthrough Project in Key Industrial Chains of Shaanxi Province

Cite

APA

Bai, Y., Zhao, X., Wang, F., Liu, D., Diao, Y., Sun, Y., Zhao, Y., Zhang, L., Bai, Y., Wang, S., Jia, P., Zhao, Y., & Zheng, X. (2026). Lung-Targeted Delivery of Nebulized α-Asaronol Attenuates Airway Inflammation and Hyperresponsiveness in Murine Asthma Models. ACS Pharmacology & Translational Science, 9(8), 2343-2357. https://doi.org/10.1021/acsptsci.6c00367

Vancouver

Bai Y, Zhao X, Wang F, Liu D, Diao Y, Sun Y, et al. Lung-Targeted Delivery of Nebulized α-Asaronol Attenuates Airway Inflammation and Hyperresponsiveness in Murine Asthma Models. ACS Pharmacology & Translational Science. 2026;9(8):2343-2357. doi:10.1021/acsptsci.6c00367

BibTeX
@article{Bai2026,
  author = {Bai, Yajun and Zhao, Xiaolong and Wang, Fei and Liu, Dan and Diao, Yujie and Sun, Ying and Zhao, Yingying and Zhang, Liyuan and Bai, Yujun and Wang, Shixiang and Jia, Pu and Zhao, Ye and Zheng, Xiaohui},
  title = {Lung-Targeted Delivery of Nebulized α-Asaronol Attenuates Airway Inflammation and Hyperresponsiveness in Murine Asthma Models},
  journal = {ACS Pharmacology & Translational Science},
  year = {2026},
  volume = {9},
  number = {8},
  pages = {2343--2357},
  doi = {10.1021/acsptsci.6c00367}
}
Start for free →